Etodolac Market
This report contains market size and forecasts of Etodolac in global, including the following mar ... Read More
1 Introduction to Research & Analysis Reports 1.1 Selective Cox-2 Inhibitors Market Definition 1.2 Market Segments 1.2.1 Market by Type 1.2.2 Market by Application 1.3 Global Selective Cox-2 Inhibitors Market Overview 1.4 Features & Benefits of This Report 1.5 Methodology & Sources of Information 1.5.1 Research Methodology 1.5.2 Research Process 1.5.3 Base Year 1.5.4 Report Assumptions & Caveats 2 Global Selective Cox-2 Inhibitors Overall Market Size 2.1 Global Selective Cox-2 Inhibitors Market Size: 2021 VS 2028 2.2 Global Selective Cox-2 Inhibitors Market Size, Prospects & Forecasts: 2017-2028 2.3 Key Market Trends, Opportunity, Drivers and Restraints 2.3.1 Market Opportunities & Trends 2.3.2 Market Drivers 2.3.3 Market Restraints 3 Company Landscape 3.1 Top Selective Cox-2 Inhibitors Players in Global Market 3.2 Top Global Selective Cox-2 Inhibitors Companies Ranked by Revenue 3.3 Global Selective Cox-2 Inhibitors Revenue by Companies 3.4 Top 3 and Top 5 Selective Cox-2 Inhibitors Companies in Global Market, by Revenue in 2021 3.5 Global Companies Selective Cox-2 Inhibitors Product Type 3.6 Tier 1, Tier 2 and Tier 3 Selective Cox-2 Inhibitors Players in Global Market 3.6.1 List of Global Tier 1 Selective Cox-2 Inhibitors Companies 3.6.2 List of Global Tier 2 and Tier 3 Selective Cox-2 Inhibitors Companies 4 Market Sights by Product 4.1 Overview 4.1.1 by Type - Global Selective Cox-2 Inhibitors Market Size Markets, 2021 & 2028 4.1.2 Meloxicam 4.1.3 Celecoxib 4.1.4 Etoricoxib 4.1.5 Imrecoxib 4.1.6 Etodolac 4.1.7 Parecoxib 4.1.8 Other 4.2 By Type - Global Selective Cox-2 Inhibitors Revenue & Forecasts 4.2.1 By Type - Global Selective Cox-2 Inhibitors Revenue, 2017-2022 4.2.2 By Type - Global Selective Cox-2 Inhibitors Revenue, 2023-2028 4.2.3 By Type - Global Selective Cox-2 Inhibitors Revenue Market Share, 2017-2028 5 Sights by Application 5.1 Overview 5.1.1 By Application - Global Selective Cox-2 Inhibitors Market Size, 2021 & 2028 5.1.2 Rheumatoid Arthritis 5.1.3 Osteoarthritis 5.1.4 Spondylosis Chronica Ankylopoietica 5.1.5 Other 5.2 By Application - Global Selective Cox-2 Inhibitors Revenue & Forecasts 5.2.1 By Application - Global Selective Cox-2 Inhibitors Revenue, 2017-2022 5.2.2 By Application - Global Selective Cox-2 Inhibitors Revenue, 2023-2028 5.2.3 By Application - Global Selective Cox-2 Inhibitors Revenue Market Share, 2017-2028 6 Sights by Region 6.1 By Region - Global Selective Cox-2 Inhibitors Market Size, 2021 & 2028 6.2 By Region - Global Selective Cox-2 Inhibitors Revenue & Forecasts 6.2.1 By Region - Global Selective Cox-2 Inhibitors Revenue, 2017-2022 6.2.2 By Region - Global Selective Cox-2 Inhibitors Revenue, 2023-2028 6.2.3 By Region - Global Selective Cox-2 Inhibitors Revenue Market Share, 2017-2028 6.3 North America 6.3.1 By Country - North America Selective Cox-2 Inhibitors Revenue, 2017-2028 6.3.2 US Selective Cox-2 Inhibitors Market Size, 2017-2028 6.3.3 Canada Selective Cox-2 Inhibitors Market Size, 2017-2028 6.3.4 Mexico Selective Cox-2 Inhibitors Market Size, 2017-2028 6.4 Europe 6.4.1 By Country - Europe Selective Cox-2 Inhibitors Revenue, 2017-2028 6.4.2 Germany Selective Cox-2 Inhibitors Market Size, 2017-2028 6.4.3 France Selective Cox-2 Inhibitors Market Size, 2017-2028 6.4.4 U.K. Selective Cox-2 Inhibitors Market Size, 2017-2028 6.4.5 Italy Selective Cox-2 Inhibitors Market Size, 2017-2028 6.4.6 Russia Selective Cox-2 Inhibitors Market Size, 2017-2028 6.4.7 Nordic Countries Selective Cox-2 Inhibitors Market Size, 2017-2028 6.4.8 Benelux Selective Cox-2 Inhibitors Market Size, 2017-2028 6.5 Asia 6.5.1 By Region - Asia Selective Cox-2 Inhibitors Revenue, 2017-2028 6.5.2 China Selective Cox-2 Inhibitors Market Size, 2017-2028 6.5.3 Japan Selective Cox-2 Inhibitors Market Size, 2017-2028 6.5.4 South Korea Selective Cox-2 Inhibitors Market Size, 2017-2028 6.5.5 Southeast Asia Selective Cox-2 Inhibitors Market Size, 2017-2028 6.5.6 India Selective Cox-2 Inhibitors Market Size, 2017-2028 6.6 South America 6.6.1 By Country - South America Selective Cox-2 Inhibitors Revenue, 2017-2028 6.6.2 Brazil Selective Cox-2 Inhibitors Market Size, 2017-2028 6.6.3 Argentina Selective Cox-2 Inhibitors Market Size, 2017-2028 6.7 Middle East & Africa 6.7.1 By Country - Middle East & Africa Selective Cox-2 Inhibitors Revenue, 2017-2028 6.7.2 Turkey Selective Cox-2 Inhibitors Market Size, 2017-2028 6.7.3 Israel Selective Cox-2 Inhibitors Market Size, 2017-2028 6.7.4 Saudi Arabia Selective Cox-2 Inhibitors Market Size, 2017-2028 6.7.5 UAE Selective Cox-2 Inhibitors Market Size, 2017-2028 7 Players Profiles 7.1 Boehringer-Ingelheim 7.1.1 Boehringer-Ingelheim Corporate Summary 7.1.2 Boehringer-Ingelheim Business Overview 7.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Major Product Offerings 7.1.4 Boehringer-Ingelheim Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.1.5 Boehringer-Ingelheim Key News 7.2 TerSera Therapeutics 7.2.1 TerSera Therapeutics Corporate Summary 7.2.2 TerSera Therapeutics Business Overview 7.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Major Product Offerings 7.2.4 TerSera Therapeutics Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.2.5 TerSera Therapeutics Key News 7.3 Iroko Pharmaceuticals 7.3.1 Iroko Pharmaceuticals Corporate Summary 7.3.2 Iroko Pharmaceuticals Business Overview 7.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Major Product Offerings 7.3.4 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.3.5 Iroko Pharmaceuticals Key News 7.4 Apotex 7.4.1 Apotex Corporate Summary 7.4.2 Apotex Business Overview 7.4.3 Apotex Selective Cox-2 Inhibitors Major Product Offerings 7.4.4 Apotex Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.4.5 Apotex Key News 7.5 Yung Shin Pharmaceutical 7.5.1 Yung Shin Pharmaceutical Corporate Summary 7.5.2 Yung Shin Pharmaceutical Business Overview 7.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Major Product Offerings 7.5.4 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.5.5 Yung Shin Pharmaceutical Key News 7.6 Breckenridge Pharmaceutical 7.6.1 Breckenridge Pharmaceutical Corporate Summary 7.6.2 Breckenridge Pharmaceutical Business Overview 7.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Major Product Offerings 7.6.4 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.6.5 Breckenridge Pharmaceutical Key News 7.7 Meda Pharmaceuticals 7.7.1 Meda Pharmaceuticals Corporate Summary 7.7.2 Meda Pharmaceuticals Business Overview 7.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Major Product Offerings 7.7.4 Meda Pharmaceuticals Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.7.5 Meda Pharmaceuticals Key News 7.8 Cipla 7.8.1 Cipla Corporate Summary 7.8.2 Cipla Business Overview 7.8.3 Cipla Selective Cox-2 Inhibitors Major Product Offerings 7.8.4 Cipla Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.8.5 Cipla Key News 7.9 Glenmark Pharmaceuticals 7.9.1 Glenmark Pharmaceuticals Corporate Summary 7.9.2 Glenmark Pharmaceuticals Business Overview 7.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Major Product Offerings 7.9.4 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.9.5 Glenmark Pharmaceuticals Key News 7.10 Teva 7.10.1 Teva Corporate Summary 7.10.2 Teva Business Overview 7.10.3 Teva Selective Cox-2 Inhibitors Major Product Offerings 7.10.4 Teva Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.10.5 Teva Key News 7.11 PuraCap Pharmaceutical 7.11.1 PuraCap Pharmaceutical Corporate Summary 7.11.2 PuraCap Pharmaceutical Business Overview 7.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Major Product Offerings 7.11.4 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.11.5 PuraCap Pharmaceutical Key News 7.12 Almirall Limited 7.12.1 Almirall Limited Corporate Summary 7.12.2 Almirall Limited Business Overview 7.12.3 Almirall Limited Selective Cox-2 Inhibitors Major Product Offerings 7.12.4 Almirall Limited Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.12.5 Almirall Limited Key News 7.13 Lupin Pharmaceuticals 7.13.1 Lupin Pharmaceuticals Corporate Summary 7.13.2 Lupin Pharmaceuticals Business Overview 7.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Major Product Offerings 7.13.4 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.13.5 Lupin Pharmaceuticals Key News 7.14 Aurobindo Pharma 7.14.1 Aurobindo Pharma Corporate Summary 7.14.2 Aurobindo Pharma Business Overview 7.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Major Product Offerings 7.14.4 Aurobindo Pharma Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.14.5 Aurobindo Pharma Key News 7.15 Pfizer 7.15.1 Pfizer Corporate Summary 7.15.2 Pfizer Business Overview 7.15.3 Pfizer Selective Cox-2 Inhibitors Major Product Offerings 7.15.4 Pfizer Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.15.5 Pfizer Key News 7.16 Mylan 7.16.1 Mylan Corporate Summary 7.16.2 Mylan Business Overview 7.16.3 Mylan Selective Cox-2 Inhibitors Major Product Offerings 7.16.4 Mylan Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.16.5 Mylan Key News 7.17 Takeda 7.17.1 Takeda Corporate Summary 7.17.2 Takeda Business Overview 7.17.3 Takeda Selective Cox-2 Inhibitors Major Product Offerings 7.17.4 Takeda Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.17.5 Takeda Key News 7.18 Bayer 7.18.1 Bayer Corporate Summary 7.18.2 Bayer Business Overview 7.18.3 Bayer Selective Cox-2 Inhibitors Major Product Offerings 7.18.4 Bayer Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.18.5 Bayer Key News 7.19 Novacap 7.19.1 Novacap Corporate Summary 7.19.2 Novacap Business Overview 7.19.3 Novacap Selective Cox-2 Inhibitors Major Product Offerings 7.19.4 Novacap Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.19.5 Novacap Key News 7.20 Abbott 7.20.1 Abbott Corporate Summary 7.20.2 Abbott Business Overview 7.20.3 Abbott Selective Cox-2 Inhibitors Major Product Offerings 7.20.4 Abbott Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.20.5 Abbott Key News 7.21 Geri-Care 7.21.1 Geri-Care Corporate Summary 7.21.2 Geri-Care Business Overview 7.21.3 Geri-Care Selective Cox-2 Inhibitors Major Product Offerings 7.21.4 Geri-Care Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.21.5 Geri-Care Key News 7.22 Perrigo 7.22.1 Perrigo Corporate Summary 7.22.2 Perrigo Business Overview 7.22.3 Perrigo Selective Cox-2 Inhibitors Major Product Offerings 7.22.4 Perrigo Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.22.5 Perrigo Key News 7.23 Kopran 7.23.1 Kopran Corporate Summary 7.23.2 Kopran Business Overview 7.23.3 Kopran Selective Cox-2 Inhibitors Major Product Offerings 7.23.4 Kopran Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.23.5 Kopran Key News 7.24 Merck 7.24.1 Merck Corporate Summary 7.24.2 Merck Business Overview 7.24.3 Merck Selective Cox-2 Inhibitors Major Product Offerings 7.24.4 Merck Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.24.5 Merck Key News 7.25 Hengrui pharmaceutical 7.25.1 Hengrui pharmaceutical Corporate Summary 7.25.2 Hengrui pharmaceutical Business Overview 7.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Major Product Offerings 7.25.4 Hengrui pharmaceutical Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.25.5 Hengrui pharmaceutical Key News 7.26 Kelun Group 7.26.1 Kelun Group Corporate Summary 7.26.2 Kelun Group Business Overview 7.26.3 Kelun Group Selective Cox-2 Inhibitors Major Product Offerings 7.26.4 Kelun Group Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.26.5 Kelun Group Key News 7.27 Qilu Pharmaceutical 7.27.1 Qilu Pharmaceutical Corporate Summary 7.27.2 Qilu Pharmaceutical Business Overview 7.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Major Product Offerings 7.27.4 Qilu Pharmaceutical Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.27.5 Qilu Pharmaceutical Key News 7.28 Taro Pharmaceuticals 7.28.1 Taro Pharmaceuticals Corporate Summary 7.28.2 Taro Pharmaceuticals Business Overview 7.28.3 Taro Pharmaceuticals Selective Cox-2 Inhibitors Major Product Offerings 7.28.4 Taro Pharmaceuticals Selective Cox-2 Inhibitors Revenue in Global Market (2017-2022) 7.28.5 Taro Pharmaceuticals Key News 8 Conclusion 9 Appendix 9.1 Note 9.2 Examples of Clients 9.3 Disclaimer
List of Tables Table 1. Selective Cox-2 Inhibitors Market Opportunities & Trends in Global Market Table 2. Selective Cox-2 Inhibitors Market Drivers in Global Market Table 3. Selective Cox-2 Inhibitors Market Restraints in Global Market Table 4. Key Players of Selective Cox-2 Inhibitors in Global Market Table 5. Top Selective Cox-2 Inhibitors Players in Global Market, Ranking by Revenue (2021) Table 6. Global Selective Cox-2 Inhibitors Revenue by Companies, (US$, Mn), 2017-2022 Table 7. Global Selective Cox-2 Inhibitors Revenue Share by Companies, 2017-2022 Table 8. Global Companies Selective Cox-2 Inhibitors Product Type Table 9. List of Global Tier 1 Selective Cox-2 Inhibitors Companies, Revenue (US$, Mn) in 2021 and Market Share Table 10. List of Global Tier 2 and Tier 3 Selective Cox-2 Inhibitors Companies, Revenue (US$, Mn) in 2021 and Market Share Table 11. By Type – Global Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2021 & 2028 Table 12. By Type - Selective Cox-2 Inhibitors Revenue in Global (US$, Mn), 2017-2022 Table 13. By Type - Selective Cox-2 Inhibitors Revenue in Global (US$, Mn), 2023-2028 Table 14. By Application – Global Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2021 & 2028 Table 15. By Application - Selective Cox-2 Inhibitors Revenue in Global (US$, Mn), 2017-2022 Table 16. By Application - Selective Cox-2 Inhibitors Revenue in Global (US$, Mn), 2023-2028 Table 17. By Region – Global Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2021 & 2028 Table 18. By Region - Global Selective Cox-2 Inhibitors Revenue (US$, Mn), 2017-2022 Table 19. By Region - Global Selective Cox-2 Inhibitors Revenue (US$, Mn), 2023-2028 Table 20. By Country - North America Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2022 Table 21. By Country - North America Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2023-2028 Table 22. By Country - Europe Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2022 Table 23. By Country - Europe Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2023-2028 Table 24. By Region - Asia Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2022 Table 25. By Region - Asia Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2023-2028 Table 26. By Country - South America Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2022 Table 27. By Country - South America Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2023-2028 Table 28. By Country - Middle East & Africa Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2022 Table 29. By Country - Middle East & Africa Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2023-2028 Table 30. Boehringer-Ingelheim Corporate Summary Table 31. Boehringer-Ingelheim Selective Cox-2 Inhibitors Product Offerings Table 32. Boehringer-Ingelheim Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 33. TerSera Therapeutics Corporate Summary Table 34. TerSera Therapeutics Selective Cox-2 Inhibitors Product Offerings Table 35. TerSera Therapeutics Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 36. Iroko Pharmaceuticals Corporate Summary Table 37. Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product Offerings Table 38. Iroko Pharmaceuticals Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 39. Apotex Corporate Summary Table 40. Apotex Selective Cox-2 Inhibitors Product Offerings Table 41. Apotex Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 42. Yung Shin Pharmaceutical Corporate Summary Table 43. Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Product Offerings Table 44. Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 45. Breckenridge Pharmaceutical Corporate Summary Table 46. Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product Offerings Table 47. Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 48. Meda Pharmaceuticals Corporate Summary Table 49. Meda Pharmaceuticals Selective Cox-2 Inhibitors Product Offerings Table 50. Meda Pharmaceuticals Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 51. Cipla Corporate Summary Table 52. Cipla Selective Cox-2 Inhibitors Product Offerings Table 53. Cipla Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 54. Glenmark Pharmaceuticals Corporate Summary Table 55. Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product Offerings Table 56. Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 57. Teva Corporate Summary Table 58. Teva Selective Cox-2 Inhibitors Product Offerings Table 59. Teva Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 60. PuraCap Pharmaceutical Corporate Summary Table 61. PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product Offerings Table 62. PuraCap Pharmaceutical Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 63. Almirall Limited Corporate Summary Table 64. Almirall Limited Selective Cox-2 Inhibitors Product Offerings Table 65. Almirall Limited Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 66. Lupin Pharmaceuticals Corporate Summary Table 67. Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product Offerings Table 68. Lupin Pharmaceuticals Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 69. Aurobindo Pharma Corporate Summary Table 70. Aurobindo Pharma Selective Cox-2 Inhibitors Product Offerings Table 71. Aurobindo Pharma Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 72. Pfizer Corporate Summary Table 73. Pfizer Selective Cox-2 Inhibitors Product Offerings Table 74. Pfizer Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 75. Mylan Corporate Summary Table 76. Mylan Selective Cox-2 Inhibitors Product Offerings Table 77. Mylan Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 78. Takeda Corporate Summary Table 79. Takeda Selective Cox-2 Inhibitors Product Offerings Table 80. Takeda Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 81. Bayer Corporate Summary Table 82. Bayer Selective Cox-2 Inhibitors Product Offerings Table 83. Bayer Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 84. Novacap Corporate Summary Table 85. Novacap Selective Cox-2 Inhibitors Product Offerings Table 86. Novacap Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 87. Abbott Corporate Summary Table 88. Abbott Selective Cox-2 Inhibitors Product Offerings Table 89. Abbott Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 90. Geri-Care Corporate Summary Table 91. Geri-Care Selective Cox-2 Inhibitors Product Offerings Table 92. Geri-Care Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 93. Perrigo Corporate Summary Table 94. Perrigo Selective Cox-2 Inhibitors Product Offerings Table 95. Perrigo Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 96. Kopran Corporate Summary Table 97. Kopran Selective Cox-2 Inhibitors Product Offerings Table 98. Kopran Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 99. Merck Corporate Summary Table 100. Merck Selective Cox-2 Inhibitors Product Offerings Table 101. Merck Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 102. Hengrui pharmaceutical Corporate Summary Table 103. Hengrui pharmaceutical Selective Cox-2 Inhibitors Product Offerings Table 104. Hengrui pharmaceutical Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 105. Kelun Group Corporate Summary Table 106. Kelun Group Selective Cox-2 Inhibitors Product Offerings Table 107. Kelun Group Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 108. Qilu Pharmaceutical Corporate Summary Table 109. Qilu Pharmaceutical Selective Cox-2 Inhibitors Product Offerings Table 110. Qilu Pharmaceutical Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) Table 111. Taro Pharmaceuticals Corporate Summary Table 112. Taro Pharmaceuticals Selective Cox-2 Inhibitors Product Offerings Table 113. Taro Pharmaceuticals Selective Cox-2 Inhibitors Revenue (US$, Mn), (2017-2022) List of Figures Figure 1. Selective Cox-2 Inhibitors Segment by Type in 2021 Figure 2. Selective Cox-2 Inhibitors Segment by Application in 2021 Figure 3. Global Selective Cox-2 Inhibitors Market Overview: 2021 Figure 4. Key Caveats Figure 5. Global Selective Cox-2 Inhibitors Market Size: 2021 VS 2028 (US$, Mn) Figure 6. Global Selective Cox-2 Inhibitors Revenue, 2017-2028 (US$, Mn) Figure 7. The Top 3 and 5 Players Market Share by Selective Cox-2 Inhibitors Revenue in 2021 Figure 8. By Type - Global Selective Cox-2 Inhibitors Revenue Market Share, 2017-2028 Figure 9. By Application - Global Selective Cox-2 Inhibitors Revenue Market Share, 2017-2028 Figure 10. By Region - Global Selective Cox-2 Inhibitors Revenue Market Share, 2017-2028 Figure 11. By Country - North America Selective Cox-2 Inhibitors Revenue Market Share, 2017-2028 Figure 12. US Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 13. Canada Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 14. Mexico Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 15. By Country - Europe Selective Cox-2 Inhibitors Revenue Market Share, 2017-2028 Figure 16. Germany Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 17. France Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 18. U.K. Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 19. Italy Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 20. Russia Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 21. Nordic Countries Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 22. Benelux Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 23. By Region - Asia Selective Cox-2 Inhibitors Revenue Market Share, 2017-2028 Figure 24. China Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 25. Japan Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 26. South Korea Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 27. Southeast Asia Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 28. India Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 29. By Country - South America Selective Cox-2 Inhibitors Revenue Market Share, 2017-2028 Figure 30. Brazil Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 31. Argentina Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 32. By Country - Middle East & Africa Selective Cox-2 Inhibitors Revenue Market Share, 2017-2028 Figure 33. Turkey Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 34. Israel Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 35. Saudi Arabia Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 36. UAE Selective Cox-2 Inhibitors Revenue, (US$, Mn), 2017-2028 Figure 37. Boehringer-Ingelheim Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 38. TerSera Therapeutics Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 39. Iroko Pharmaceuticals Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 40. Apotex Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 41. Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 42. Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 43. Meda Pharmaceuticals Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 44. Cipla Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 45. Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 46. Teva Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 47. PuraCap Pharmaceutical Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 48. Almirall Limited Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 49. Lupin Pharmaceuticals Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 50. Aurobindo Pharma Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 51. Pfizer Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 52. Mylan Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 53. Takeda Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 54. Bayer Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 55. Novacap Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 56. Abbott Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 57. Geri-Care Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 58. Perrigo Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 59. Kopran Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 60. Merck Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 61. Hengrui pharmaceutical Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 62. Kelun Group Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 63. Qilu Pharmaceutical Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022) Figure 64. Taro Pharmaceuticals Selective Cox-2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
112
This report contains market size and forecasts of Etodolac in global, including the following mar ... Read More
This report contains market size and forecasts of Non-Peptide Drugs of Angiotensin II Receptor An ... Read More
This report contains market size and forecasts of Allisartan Isoproxil in global, including the f ... Read More
This report contains market size and forecasts of Apatinib in global, including the following mar ... Read More